Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Apatinib in Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
NCT06475209Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in small cell lung cancer (SCLC), sponsored by Tangdu Hospital. Started Jun 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06475209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475209.